The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate adverse events.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate adverse events.